Unicycive Therapeutics financials
$4.55−1.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $675.0K | $951.0K | $0.00 |
| Gross profit | $0.00 | $0.00 | $675.0K | $951.0K | $0.00 |
| Gross margin | — | — | 100.0% | 100.0% | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M |
| Net income | -$26.6M | -$37.8M | -$31.4M | -$18.1M | -$10.0M |
| Net margin | — | — | −4653.5% | −1898.8% | — |
| Diluted EPS | $-1.67 | $-5.65 | $-12.80 | $-12.00 | $-8.60 |
| EBITDA | -$29.5M | -$32.1M | -$20.8M | -$18.0M | -$9.0M |
| Operating cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$8.0M |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$8.0M |
| Diluted shares | 15.9M | 6.7M | 2.5M | 1.5M | 1.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $29.2M | $26.1M | $9.7M | $455.0K | $16.6M |
| Short-term investments | $12.1M | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M |
| Shareholders' equity | $30.2M | $7.4M | -$3.8M | -$466.0K | $16.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology